Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.

Abstract excerpt

AIM: This study aims to evaluate the prognostic role of the KRAS G12C mutation in patients with advanced non-small cell lung cancer and PD-L1 expression ≥50% who are treated with immune checkpoint inhibitor monotherapy. METHODS: We conducted a systematic review of clinical studies fulfilling the following criteria: (1) enrolling patients with advanced/metastatic non-small cell lung cancer with high PD-L1 tumour...

Topics

Join the communities discussing this publication.

• B7-H1 Antigen
• Carcinoma, Non-Small-Cell Lung
• Immune Checkpoint Inhibitors
• Immunotherapy
• Lung Neoplasms